4//SEC Filing
VANLANDINGHAM JACOB PH.D 4
Accession 0001683168-22-004244
CIK 0001626644other
Filed
Jun 7, 8:00 PM ET
Accepted
Jun 8, 5:18 PM ET
Size
5.5 KB
Accession
0001683168-22-004244
Insider Transaction Report
Form 4
VANLANDINGHAM JACOB PH.D
Director
Transactions
- Award
Stock Option (Right to Buy)
2022-05-19$0.30/sh+100,000$30,000→ 1,100,000 totalExercise: $0.30Exp: 2032-05-19→ Common Stock (100,000 underlying)
Footnotes (1)
- [F1]Vesting Schedule: 50% vest on first dosed subject of Phase 2 Trial; 50% on last dosed subject of Phase 2 Trial.
Documents
Issuer
Odyssey Health, Inc.
CIK 0001626644
Entity typeother
Related Parties
1- filerCIK 0001794273
Filing Metadata
- Form type
- 4
- Filed
- Jun 7, 8:00 PM ET
- Accepted
- Jun 8, 5:18 PM ET
- Size
- 5.5 KB